e.g. mhealth
Search Results (1 to 10 of 10 Results)
Download search results: CSV END BibTex RIS
Skip search results from other journals and go to results- 2 JMIR Medical Informatics
- 2 JMIR mHealth and uHealth
- 2 Journal of Medical Internet Research
- 1 JMIR Cancer
- 1 JMIR Cardio
- 1 JMIR Formative Research
- 1 JMIR Human Factors
- 0 Medicine 2.0
- 0 Interactive Journal of Medical Research
- 0 iProceedings
- 0 JMIR Research Protocols
- 0 JMIR Public Health and Surveillance
- 0 JMIR Serious Games
- 0 JMIR Mental Health
- 0 JMIR Rehabilitation and Assistive Technologies
- 0 JMIR Preprints
- 0 JMIR Bioinformatics and Biotechnology
- 0 JMIR Medical Education
- 0 JMIR Challenges
- 0 JMIR Diabetes
- 0 JMIR Biomedical Engineering
- 0 JMIR Data
- 0 Journal of Participatory Medicine
- 0 JMIR Dermatology
- 0 JMIR Pediatrics and Parenting
- 0 JMIR Aging
- 0 JMIR Perioperative Medicine
- 0 JMIR Nursing
- 0 JMIRx Med
- 0 JMIRx Bio
- 0 JMIR Infodemiology
- 0 Transfer Hub (manuscript eXchange)
- 0 JMIR AI
- 0 JMIR Neurotechnology
- 0 Asian/Pacific Island Nursing Journal
- 0 Online Journal of Public Health Informatics
- 0 JMIR XR and Spatial Computing (JMXR)
Additionally, the exclusive focus on edoxaban limits the generalizability of the findings to patients using other anticoagulants with differing dosing regimens and side effects. Broadening the intervention to encompass a more diverse patient population and various anticoagulants would strengthen the external validity and clinical relevance of the study.
Second, the 6-month follow-up period is another critical consideration, as adherence is a dynamic behavior that often fluctuates over time.
J Med Internet Res 2025;27:e69204
Download Citation: END BibTex RIS
Stroke prevention with oral anticoagulants is essential in the management of patients with atrial fibrillation (AF) [1,2]. Previous large randomized controlled trials for AF have shown improved safety and comparable efficacy of nonvitamin K antagonist oral anticoagulants (NOACs) compared with warfarin [3]. Thus, current guidelines prefer NOACs over warfarin for ischemic stroke prevention in patients with AF [1,2].
J Med Internet Res 2024;26:e65010
Download Citation: END BibTex RIS
In addition, a review of 14 SDM tools focused on choosing between Warfarin and direct oral anticoagulants from Torres Roldan et al [28] showed that the current DA developmental process rarely includes patients. The studies observed were overall unsuccessful, as only 2 of the 14 DAs reviewed improved adherence, and 3 of the 14 did not support SDM.
JMIR Cancer 2024;10:e56935
Download Citation: END BibTex RIS
Reference 6: Influence of direct oral anticoagulants on rates of oral anticoagulation for atrial fibrillation Reference 14: A systematic review on mobile health applications' education program for patients taking oral anticoagulantsanticoagulants
JMIR Cardio 2024;8:e49590
Download Citation: END BibTex RIS
With growing use since their introduction in 2010, direct oral anticoagulants (DOACs) are now the most commonly prescribed anticoagulants to prevent stroke in patients with atrial fibrillation and to prevent or treat venous thromboembolism. Despite their high degree of efficacy, DOACs remain high-risk medications that can cause severe and fatal complications when prescribed inappropriately [1,2].
JMIR Hum Factors 2023;10:e49025
Download Citation: END BibTex RIS
Due to the length of some of the documents, information was searched using keywords related to anticoagulant and antiplatelet drugs, such as “oral anticoagulants,” “anticoagulation,” “anticoagulants,” “vitamin K antagonists,” “antiaggregants,” “antiaggregation,” “acetylsalicylic acid,” and “clopidogrel.”
The information extracted from the selected documents was collected in a tabulated record in the form of rules.
JMIR Form Res 2022;6(8):e27990
Download Citation: END BibTex RIS
A recent meta-analysis found that suboptimal adherence to and persistence with direct oral anticoagulants (DOACs) is common [6]. For example, patients with AF do not take a DOAC every 4 days; one-third of the patients have less than 80% adherence; real-world persistence with DOACs is lower than in randomized controlled trials; and patients with poor adherence have a higher risk of stroke.
To date, various greater efforts in monitoring and interventions have been used to improve OAC adherence.
JMIR Mhealth Uhealth 2022;10(1):e30807
Download Citation: END BibTex RIS
Vitamin K antagonists (VKAs) in general and warfarin in particular are among the most frequently prescribed anticoagulants worldwide [1]. These drugs are used in the primary or secondary prevention of all types of thrombosis [1-3]. However, VKAs are associated with a significant risk of adverse events, due to their narrow therapeutic window, inter- and intra-individual variability, and numerous drug-drug interactions (DDIs) [1,4,5].
JMIR Med Inform 2021;9(1):e20862
Download Citation: END BibTex RIS
In this section, we use an example to demonstrate the clinical application of the NCSS, which is used to investigate the clinical effectiveness and safety between novel oral anticoagulants (NOACs) and warfarin in patients with nonvalvular atrial fibrillation (AF). According to clinical guidelines [20,21], anticoagulant therapy is recommended for AF patients to prevent the risk of ischemic stroke, which is one of the major complications of AF.
JMIR Med Inform 2019;7(3):e13329
Download Citation: END BibTex RIS
Due to their better risk-benefit profile, non-vitamin K antagonist oral anticoagulants (NOAC) are now preferred over vitamin K antagonists [10-12]. However, a strict adherence to the prescribed NOAC medication regimen is of pivotal importance for optimal stroke prevention since their anticoagulant effect lasts for only 12-24 hours after each intake [12].
JMIR Mhealth Uhealth 2017;5(7):e98
Download Citation: END BibTex RIS